Literature DB >> 22535653

Lineage extrinsic and intrinsic control of immunoregulatory cell numbers by SHIP.

Michelle M Collazo1, Kim H T Paraiso, Mi-Young Park, Amy L Hazen, William G Kerr.   

Abstract

We previously showed that germline or induced SHIP deficiency expands immuno-regulatory cell numbers in T lymphoid and myeloid lineages. We postulated these increases could be interrelated. Here, we show that myeloid-specific ablation of SHIP leads to the expansion of both myeloid-derived suppressor cell (MDSC) and regulatory T (Treg) cell numbers, indicating SHIP-dependent control of Treg-cell numbers by a myeloid cell type. Conversely, T-lineage specific ablation of SHIP leads to expansion of Treg-cell numbers, but not expansion of the MDSC compartment, indicating SHIP also has a lineage intrinsic role in limiting Treg-cell numbers. However, the SHIP-deficient myeloid cell that promotes MDSC and Treg-cell expansion is not an MDSC as they lack SHIP protein expression. Thus, regulation of MDSC numbers in vivo must be controlled in a cell-extrinsic fashion by another myeloid cell type. We had previously shown that G-CSF levels are profoundly increased in SHIP(-/-) mice, suggesting this myelopoietic growth factor could promote MDSC expansion in a cell-extrinsic fashion. Consistent with this hypothesis, we find that G-CSF is required for expansion of the MDSC splenic compartment in mice rendered SHIP-deficient as adults. Thus, SHIP controls MDSC numbers, in part, by limiting production of the myelopoietic growth factor G-CSF.
© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22535653      PMCID: PMC3816569          DOI: 10.1002/eji.201142092

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  56 in total

1.  Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer.

Authors:  Srinivas Nagaraj; Je-In Youn; Hannah Weber; Cristina Iclozan; Lily Lu; Matthew J Cotter; Colin Meyer; Carlos R Becerra; Mayer Fishman; Scott Antonia; Michael B Sporn; Karen T Liby; Bhupendra Rawal; Ji-Hyun Lee; Dmitry I Gabrilovich
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

2.  SHIP1 inhibition increases immunoregulatory capacity and triggers apoptosis of hematopoietic cancer cells.

Authors:  Robert Brooks; Gwenny M Fuhler; Sonia Iyer; Michelle J Smith; Mi-Young Park; Kim H T Paraiso; Robert W Engelman; William G Kerr
Journal:  J Immunol       Date:  2010-03-03       Impact factor: 5.422

3.  Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization.

Authors:  Matthew J Christopher; Fulu Liu; Matthew J Hilton; Fanxin Long; Daniel C Link
Journal:  Blood       Date:  2009-01-13       Impact factor: 22.113

4.  CXCL12 enhances exogenous CD4+CD25+ T cell migration and prevents embryo loss in non-obese diabetic mice.

Authors:  Yi Lin; Liang Xu; Haiyan Jin; Yanmin Zhong; Jingfang Di; Qi-de Lin
Journal:  Fertil Steril       Date:  2008-04-02       Impact factor: 7.329

5.  Inositol phosphatase SHIP1 is a primary target of miR-155.

Authors:  Ryan M O'Connell; Aadel A Chaudhuri; Dinesh S Rao; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-09       Impact factor: 11.205

6.  SHIP represses the generation of IL-3-induced M2 macrophages by inhibiting IL-4 production from basophils.

Authors:  Etsushi Kuroda; Victor Ho; Jens Ruschmann; Frann Antignano; Melisa Hamilton; Michael J Rauh; Andrey Antov; Richard A Flavell; Laura M Sly; Gerald Krystal
Journal:  J Immunol       Date:  2009-08-26       Impact factor: 5.422

7.  Protein kinase B/Akt signals impair Th17 differentiation and support natural regulatory T cell function and induced regulatory T cell formation.

Authors:  Mandy Pierau; Swen Engelmann; Dirk Reinhold; Thabo Lapp; Burkhart Schraven; Ursula H Bommhardt
Journal:  J Immunol       Date:  2009-10-19       Impact factor: 5.422

8.  Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling.

Authors:  Christina Gewinner; Zhigang C Wang; Andrea Richardson; Julie Teruya-Feldstein; Dariush Etemadmoghadam; David Bowtell; Jordi Barretina; William M Lin; Lucia Rameh; Leonardo Salmena; Pier Paolo Pandolfi; Lewis C Cantley
Journal:  Cancer Cell       Date:  2009-08-04       Impact factor: 31.743

9.  Development of Foxp3(+) regulatory t cells is driven by the c-Rel enhanceosome.

Authors:  Qingguo Ruan; Vasumathi Kameswaran; Yukiko Tone; Li Li; Hsiou-Chi Liou; Mark I Greene; Masahide Tone; Youhai H Chen
Journal:  Immunity       Date:  2009-12-18       Impact factor: 31.745

10.  Targeting of the GTPase Irgm1 to the phagosomal membrane via PtdIns(3,4)P(2) and PtdIns(3,4,5)P(3) promotes immunity to mycobacteria.

Authors:  Sangeeta Tiwari; Han-Pil Choi; Takeshi Matsuzawa; Marc Pypaert; John D MacMicking
Journal:  Nat Immunol       Date:  2009-08       Impact factor: 25.606

View more
  17 in total

1.  SHIP1 regulates MSC numbers and their osteolineage commitment by limiting induction of the PI3K/Akt/β-catenin/Id2 axis.

Authors:  Sonia Iyer; Dennis R Viernes; John D Chisholm; Bryan S Margulies; William G Kerr
Journal:  Stem Cells Dev       Date:  2014-07-03       Impact factor: 3.272

Review 2.  Phenotype, development, and biological function of myeloid-derived suppressor cells.

Authors:  Yang Zhao; Tingting Wu; Steven Shao; Bingyi Shi; Yong Zhao
Journal:  Oncoimmunology       Date:  2015-10-14       Impact factor: 8.110

3.  Expression of microRNA-155 in inflammatory cells modulates liver injury.

Authors:  Delia Blaya; Beatriz Aguilar-Bravo; Fengjie Hao; Silvia Casacuberta-Serra; Mar Coll; Luis Perea; Júlia Vallverdú; Isabel Graupera; Elisa Pose; Laura Llovet; Jordi Barquinero; Francisco Javier Cubero; Juan Caballería; Pere Ginès; Pau Sancho-Bru
Journal:  Hepatology       Date:  2018-05-02       Impact factor: 17.425

4.  MicroRNA-21 and microRNA-155 promote the progression of Burkitt's lymphoma by the PI3K/AKT signaling pathway.

Authors:  Bo Han; Shuguo Wang; Hongguo Zhao
Journal:  Int J Clin Exp Pathol       Date:  2020-01-01

Review 5.  Erythropoietin, a multifaceted protein with innate and adaptive immune modulatory activity.

Authors:  Chiara Cantarelli; Andrea Angeletti; Paolo Cravedi
Journal:  Am J Transplant       Date:  2019-04-25       Impact factor: 8.086

6.  Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism.

Authors:  Siqi Chen; Long Wang; Jie Fan; Cong Ye; Donye Dominguez; Yi Zhang; Tyler J Curiel; Deyu Fang; Timothy M Kuzel; Bin Zhang
Journal:  Cancer Res       Date:  2014-12-10       Impact factor: 12.701

7.  Loss of lipid phosphatase SHIP1 promotes macrophage differentiation through suppression of dendritic cell differentiation.

Authors:  Eui Young So; Changqi Sun; Anthony M Reginato; Patrycia M Dubielecka; Toru Ouchi; Olin D Liang
Journal:  Cancer Biol Ther       Date:  2018-10-02       Impact factor: 4.742

8.  SHIP-1 deficiency in the myeloid compartment is insufficient to induce myeloid expansion or chronic inflammation.

Authors:  M J Maxwell; N Srivastava; M-Y Park; E Tsantikos; R W Engelman; W G Kerr; M L Hibbs
Journal:  Genes Immun       Date:  2014-03-06       Impact factor: 2.676

Review 9.  Discovery and development of small molecule SHIP phosphatase modulators.

Authors:  William G Kerr; John D Chisholm; Dennis R Viernes; Lydia B Choi
Journal:  Med Res Rev       Date:  2013-12-02       Impact factor: 12.944

10.  Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: success, disappointment, and new opportunities.

Authors:  Matthew D Blunt; Stephen G Ward
Journal:  Front Immunol       Date:  2012-08-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.